Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
03 nov. 2022 08h30 HE
|
Sight Sciences, Inc.
Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery.Despite glaucoma medications and prior microbypass stenting, target IOP may no...
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
20 oct. 2022 17h20 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)
29 sept. 2022 08h30 HE
|
Sight Sciences, Inc.
Randomized, controlled clinical trial data on advanced dry eye patients from the OLYMPIA trial recently published in Clinical OphthalmologyStudy authors concluded that the TearCare procedure delivered...
Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting
28 sept. 2022 08h30 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI...
Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting
16 sept. 2022 08h00 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. announced today that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European...
Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®
13 sept. 2022 03h01 HE
|
Sight Sciences, Inc.
310-patient RCT designed to evaluate the superiority of TearCare® (device) vs Restasis® (drug) in patients with chronic dry eye disease is now fully enrolled6-Month efficacy results expected by Summer...
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
02 sept. 2022 08h00 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
25 août 2022 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy
23 août 2022 08h03 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
16 août 2022 08h01 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...